These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 38583439)

  • 1. Osteoprotegerin and receptor activator of the nuclear factor kappa B ligand (RANKL) in healthy pubertal girls - relationships with physical growth and classical bone turnover markers.
    Kulik-Rechberger B; Kozłowska M
    J Physiol Pharmacol; 2024 Feb; 75(1):. PubMed ID: 38583439
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Circadian concentrations of free testosterone, selected markers of bone metabolism, osteoprotegerin and its ligand sRANKL in obese postmenopausal women.
    Ostrowska Z; Kos-Kudła B; Marek B; Kajdaniuk D; Wołkowska-Pokrywa K
    Postepy Hig Med Dosw (Online); 2011 Oct; 65():658-67. PubMed ID: 22100799
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bone turnover, osteoprotegerin/RANKL and inflammation with antiretroviral initiation: tenofovir versus non-tenofovir regimens.
    Brown TT; Ross AC; Storer N; Labbato D; McComsey GA
    Antivir Ther; 2011; 16(7):1063-72. PubMed ID: 22024522
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protective effect of zinc supplementation against cadmium-induced oxidative stress and the RANK/RANKL/OPG system imbalance in the bone tissue of rats.
    Brzóska MM; Rogalska J
    Toxicol Appl Pharmacol; 2013 Oct; 272(1):208-20. PubMed ID: 23726800
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Abnormal bone remodeling process is due to an imbalance in the receptor activator of nuclear factor-kappaB ligand (RANKL)/osteoprotegerin (OPG) axis in patients with solid tumors metastatic to the skeleton.
    Mountzios G; Dimopoulos MA; Bamias A; Papadopoulos G; Kastritis E; Syrigos K; Pavlakis G; Terpos E
    Acta Oncol; 2007; 46(2):221-9. PubMed ID: 17453373
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selected pro-inflammatory cytokines, bone metabolism, osteoprotegerin, and receptor activator of nuclear factor-kB ligand in girls with anorexia nervosa.
    Ostrowska Z; Ziora K; Oświęcimska J; Marek B; Świętochowska E; Kajdaniuk D; Strzelczyk J; Cieślicka A; Wołkowska-Pokrywa K; Kos-Kudła B
    Endokrynol Pol; 2015; 66(4):313-21. PubMed ID: 26323468
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TGF-β1, bone metabolism, osteoprotegerin, and soluble receptor activator of nuclear factor-kB ligand in girls with anorexia nervosa.
    Ostrowska Z; Ziora K; Oświęcimska J; Świętochowska E; Marek B; Kajdaniuk D; Strzelczyk J; Gołąbek K; Wołkowska-Pokrywa K; Kos-Kudła B
    Endokrynol Pol; 2016; 67(5):493-500. PubMed ID: 27828689
    [TBL] [Abstract][Full Text] [Related]  

  • 8.  Dehydroepiandrosterone sulfate, osteoprotegerin and its soluble ligand sRANKL and bone metabolism in girls with anorexia nervosa.
    Ostrowska Z; Ziora K; Oświęcimska J; Swiętochowska E; Wołkowska-Pokrywa K
    Postepy Hig Med Dosw (Online); 2012 Sep; 66():655-62. PubMed ID: 23001207
    [TBL] [Abstract][Full Text] [Related]  

  • 9. RANKL/RANK/OPG system and bone status in females with anorexia nervosa.
    Ostrowska Z; Ziora K; Oświęcimska J; Swiętochowska E; Szapska B; Wołkowska-Pokrywa K; Dyduch A
    Bone; 2012 Jan; 50(1):156-60. PubMed ID: 22001124
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association between omentin-1, bone metabolism markers, and cytokines of the RANKL/RANK/OPG system in girls with anorexia nervosa.
    Gołąbek K; Ostrowska Z; Ziora K; Oświęcimska J; Świętochowska E; Marek B; Kajdaniuk D; Strzelczyk J; Kos-Kudła B
    Endokrynol Pol; 2015; 66(6):514-20. PubMed ID: 26662650
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Regulatory effect of parathyroid hormone on sRANKL-osteoprotegerin in hemodialysis patients with renal bone disease.
    Doumouchtsis K; Perrea D; Doumouchtsis S; Tziamalis M; Poulakou M; Vlachos I; Kostakis A
    Ther Apher Dial; 2009 Feb; 13(1):49-55. PubMed ID: 19379170
    [TBL] [Abstract][Full Text] [Related]  

  • 12. sRANKL/osteoprotegerin complex and biochemical markers in a cohort of male and female hemodialysis patients.
    Doumouchtsis KK; Kostakis AI; Doumouchtsis SK; Tziamalis MP; Tsigris C; Kostaki MA; Perrea DN
    J Endocrinol Invest; 2007 Oct; 30(9):762-6. PubMed ID: 17993768
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bone metabolism, osteoprotegerin, receptor activator of nuclear factor-κB ligand and selected adipose tissue hormones in girls with anorexia nervosa.
    Ostrowska Z; Ziora K; Oświęcimska J; Świętochowska E; Marek B; Kajdaniuk D; Wołkowska-Pokrywa K; Kos-Kudła B
    Endokrynol Pol; 2014; 65(1):33-9. PubMed ID: 24549600
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The key role of proinflammatory cytokines, matrix proteins, RANKL/OPG and Wnt/β-catenin in bone healing of hip arthroplasty patients.
    Cassuto J; Folestad A; Göthlin J; Malchau H; Kärrholm J
    Bone; 2018 Feb; 107():66-77. PubMed ID: 29129760
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The relationship between chemerin, bone metabolism, the RANKL/RANK/OPG system, and bone mineral density in girls with anorexia nervosa.
    Ostrowska Z; Morawiecka-Pietrzak M; Pluskiewicz W; Świętochowska E; Strzelczyk J; Gołąbek K; Gaździcka J; Ziora K
    Endokrynol Pol; 2022; 73(1):26-34. PubMed ID: 35119086
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Implications of measuring soluble receptor activators of nuclear factor-kappaB ligand and osteoprotegerin in bone metabolism of elderly women.
    Chiba Y; Onouchi T; Ikeda T; Adachi J; Tamura Y; Horiuchi T
    Gerontology; 2009; 55(3):275-80. PubMed ID: 19158438
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Variations along the 24-hour cycle of circulating osteoprotegerin and soluble RANKL: a rhythmometric analysis.
    Dovio A; Generali D; Tampellini M; Berruti A; Tedoldi S; Torta M; Bonardi S; Tucci M; Allevi G; Aguggini S; Bottini A; Dogliotti L; Angeli A
    Osteoporos Int; 2008 Jan; 19(1):113-7. PubMed ID: 17703272
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Changes in the serum levels of osteoprotegerin and soluble receptor activator for nuclear factor kappaB ligand after estrogen-progestogen therapy and their relationships with changes in bone mass in postmenopausal women.
    Kim JG; Kim JH; Lee DO; Kim H; Kim JY; Suh CS; Kim SH; Choi YM
    Menopause; 2008; 15(2):357-62. PubMed ID: 17925661
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selected adipose tissue hormones, bone metabolism, osteoprotegerin and receptor activator of nuclear factor-kB ligand in postmenopausal obese women.
    Ostrowska Z; Świętochowska E; Marek B; Kajdaniuk D; Tyrpień-Golder K; Wołkowska-Pokrywa K; Damasiewicz-Bodzek A; Kos-Kudła B
    Endokrynol Pol; 2014; 65(6):438-48. PubMed ID: 25554611
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum osteoprotegrin (OPG) and receptor activator of nuclear factor kappaB (RANKL) in healthy children and adolescents.
    Wasilewska A; Rybi-Szuminska AA; Zoch-Zwierz W
    J Pediatr Endocrinol Metab; 2009 Dec; 22(12):1099-104. PubMed ID: 20333868
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.